The metabolic pathways of androgens and processes by which androgens induce re-growth after androgen deprivation therapy in prostate cancer have not been fully elucidated. In this study, finasteride decreased PSA secretion in medium containing testosterone, androstenedione, androstenediol and dehydroepiandrosterone, whereas dihydrotestosterone (DHT)-and hydroxyflutamide-induced PSA production was not inhibited by finasteride in LNCaP-FGC cells. The present data show that adrenal androgen precursors do not directly interact with androgen receptors (ARs) but are converted to DHT via the intraprostatic metabolic pathways, resulting in the induction of LNCaP activity. This is the first report confirming this mechanism experimentally and also suggest the use of combined therapies that target ARs and prevent the formation of DHT within prostate cancer cells to achieve optimal therapeutic efficacy.
Introduction
As Huggins and Hodges 1 observed that disseminated prostate cancer reacts favorably to castration or to the administration of estrogens, first-line hormonal therapy has been used to impair the production or activity of androgens, or both. At present, androgen deprivation therapy (ADT), consisting of testicular androgen blockade, the use of antiandrogens, or the combination of both (combined androgen blockade) is the standard therapy for metastatic prostate cancer. In such cases, the response rate of ADT is up to 80% with monotherapy and at more than 90% with combination therapy. However, at the metastatic stage, prostate cancer becomes resistant to ADT. If we are to improve significantly survival, new therapeutic strategies designed to avoid the emergence of resistant phenotypes must be developed.
The mechanisms of development of resistance to treatment or androgen independence have been the subject of many investigations. The AR signaling pathway might still be active during the early stage of transition to 'androgen independence' of prostate cancer cells. In fact, cancer cells adapt themselves to grow in a low androgen environment by sensitizing the AR signaling pathway. Prostate cells can amplify and overexpress the AR gene, amplify and overexpress AR coactivators, mutate AR to become activated directly by steroids other than dihydrotestosterone (DHT) such as precursor adrenal androgens, and activate AR by growth factors and cytokines. [2] [3] [4] [5] Phosphorylation of AR or ARassociated proteins occurs as observed for the estrogen receptor. 6, 7 As mentioned above, many investigators have paid attention to the AR hypersensitivity-related mechanisms of development of androgen independence. On the other hand, steroid metabolic enzymes are still expressed in prostate cancer cells, although at the androgen-independent stage, the enzyme activity has been reported to be dramatically changed, 8 thus suggesting that steroidogenic processes of androgen metabolism are also important for the development of androgen independence. These two processes, namely AR hypersensitivityrelated development mechanisms and changes in the androgen steroidogenic processes are not mutually exclusive and could simultaneously operate in prostatic cells. However, which process is the predominant pathway in the development of androgen independence remains to be determined.
The aim of the present study was to clarify the mechanism of the early stage transition to a mixed androgen-independent and androgen-sensitive status of prostate cancer cells. We first elucidated the intracellular metabolism and action of androgens, especially adrenal androgens, using LNCaP-FGC cells as model.
Materials and methods
Human prostate tumor LNCaP-FGC (American Type Culture Collection (ATCC), Manassas, VA, USA), PC3 (ATCC) and DU145 (ATCC) cells were grown in Roswell Park Memorial Institute-1640 medium (Gibco BRL, Grand Island, NY, USA) containing 10% fetal bovine serum (CSL Ltd, Victoria, Australia), 1% MEM nonessential amino acid (Gibco), 1% MEM sodium pyruvate solution 100 mM (Gibco) and 90 mg/ml kanamycin. The prostate epithelial cell line, PrEC (Clonetics, Biowhittaker, San Diego, CA, USA) was grown in PrEBM (Clonetics). Cells were maintained in an atmosphere of 5% CO 2 and 95% air at 371C. LNCaP-FGC cells, on the other hand, were plated at a concentration of 5 Â 10 5 cells per 25 cm 2 flasks (Falcon Labware, Lincoln Park, NJ, USA) and cultured in phenol-red free medium with 5% charcoal-dextran stripped of FBS 24 h before the experiment. Cells were treated with DHT, testosterone, androstenedione, androstenediol, dehydroepiandrosterone (DHEA), hydroxy-flutamide (all purchased from Sigma Chemical, St Louis, MO, USA) in the presence or absence of 5a-reductase (5-R) inhibitor finasteride (Merck Research Laboratory, Rahway, NJ, USA). Cells were also treated with finasteride alone. The cells were kept for 7 days after culture in the experimental media. The media were collected to determine PSA levels. The PSA levels in the culture media were determined by commercially available solid-phase radioimmunoassay using the Tandem PSA Test (Beckman Coulter Inc., San Diego, CA, USA) according to the manufacturer's instructions.
Total cellular RNA from the cell lines was isolated using an ISOGEN RNA isolation kit (Nippongene, Tokyo, Japan) according to the manufacturer's instructions. RNA was subjected to reverse transcription polymerase chain reaction (RT-PCR) analysis as described earlier. 9 To synthesize first-strand cDNA, 1 mg of the total RNA was reverse-transcribed using a firststrand cDNA Synthesis Kit (Roche Diagnostics, Tokyo, Japan). The first-strand DNA was then amplified by PCR using the primers shown in Table 1 . PCR was performed in a 50 ml reaction volume-containing buffer (50 mM KCl; 10 mM Tris-HCl, pH 8.4; 2.5 mM MgCl 2 and 200 mg/ml gelatin), with 200 mM of each dNTP, 400 nM of each outer primer and 2.5 units of Amplitac Gold (Roche Diagnostics, Tokyo, Japan). PCR consisted of 35 cycles of denaturation (941C, 30 s), annealing (50, 60, 60, 58, 55 and 601C for 5-R type 1, 2, 17b-hydroxysteroid dehydrogenase (17-HSD) type 2, 3, 5 and 3b-hydroxysteroid dehydrogenase (3-HSD) type 1 respectively, 45 s) and extension (721C, 60 s) followed by a final 10 min extension at 721C. The PCR products were size fractionated by 3% agarose gel electrophoresis. DNA bands were visualized with an ultraviolet transilluminator (Spectoline, Funakoshi, Tokyo, Japan).
Statistical comparisons were made using the Krusukal-Wallis test with SPSS 10.0 J software for Windows. Po0.05 was considered significant. The results are expressed as mean7s.e.m.
Results
We first studied the effect of DHT, testosterone, androstenedione, androstenediol, DHEA and hydroxyflutamide on PSA secretion in LNCaP cells. At 10 À8 , 10 -6 M resulted in a 1.46-, 2.86-, 3.78-fold dose-dependent increase in PSA production in conditioned media, respectively (P ¼ 0.019, Figure 1c ). Although these androgens and hydroxy-flutamide had some effect on cell growth, no statistically significant difference was found (data not shown). PSA production with conditioned medium was normalized to the cell numbers.
The 5-R inhibitor finasteride was first used to block the conversion of testosterone into DHT. Treatment with 10
À8
, 5Â 10 À8 and 10 À7 M finasteride alone had no significant effect on PSA secretion in the media after 7 days, of incubation (Figure 2a ). On the other hand, treatment with 10 À8 , 5Â 10 À8 and 10 À7 M finasteride resulted in 95.5, 89.4 and 80.7% (P ¼ 0.034) dosedependent inhibition of 10 À8 M testosterone-induced PSA secretion, respectively. However, the same doses of finasteride treatment had no significant effect on DHTinduced PSA secretion (Figure 2b ). These results suggest that testosterone-induced PSA production up to a large 
Discussion
The present data show that precursor adrenal androgens exert a stimulatory effect on PSA secretion in LNCaP cells following enzymatic conversion into DHT with subsequent binding to the AR. This is the first report that describes the major importance of the steroidogenic process from DHEA over the direct binding of potential androgens to hypersensitive AR in the action of precursor adrenal androgens in prostate cancer cells. This steroidogenic process should be taken into account in addition to the AR hypersensitivity-related development mechanisms leading to resistance to antiandrogen treatment in prostate cancer.
PSA has been used as parameter to study androgen action in prostate cancer. LNCaP cells are the most frequently studied AR-positive prostate cancer cell line Importance of androgen metabolism in prostate cancer K Suzuki et al with a Thr877Ala point mutation in the AR gene. These cells were established from a tumor that progressed after castration and flutamide therapy. These cells have a mutated AR that responds not only to androgens but also to flutamide with increased cellular proliferation and elevated expression of PSA. 10 LNCaP-FGC cells continuously grown in steroid-free medium did not die and the cells remained responsive to androgen. 11 These findings indicate that LNCaP-FGC cells are in an early period of mixed androgen independence and androgensensitive state. In order to evaluate the effect of androgens, anti-androgen and 5-R inhibitor on the activity of LNCaP cells, the present study investigated the levels of PSA production in conditioned media.
Prostate cells contain a variety of steroid-metabolizing enzymes required for the local formation of active androgens from precursor steroids provided by the adrenals. The main enzymes involved in local steroid metabolism are 17-HSDs, 3-HSDs and 5-Rs. At present, nine different 17-HSD isoenzymes, namely types 1, 3, 5, 7 (reductive enzymes), 2, 4, 8, 10 and 11 (oxidative enzymes) have been characterized in humans. 12 In the prostate, androstenedione is converted to testosterone by 17-HSD type 5 enzyme. 12, 13 In prostate cancer specimens, a reduced expression of 17-HSD type 2 mRNA has been detected 14 and the expression levels of the 17-HSD type 3 gene were significantly higher than those in nonmalignant tissues. 15 For 5-R, it is now clear that not only 5-R type 1 but also the type 2 isozymes are expressed in the human prostate and the inhibition of both is more effective in lowering DHT than the inhibition of a single isozyme. 16 In prostate cancer, 5-R type 1 protein levels have been reported to be increased 17 whereas type 2 immunostaining has been found to be decreased. 18 Previous reports have shown that LNCaP cells contain only 5-R type 1. 19 In the present study, we detected 17-HSD types 2, 3 and 5, 3-HSD type 1 and both 5-R types 1 and 2 mRNA expressions in LNCaP-FGC cells. Such data indicate that enzymes of androgen metabolism are well expressed in LNCaP-FGC cells.
Although finasteride mainly inhibits 5-R type 2, a high dose of finasteride can inhibit the 5-R type 1 enzyme in LNCaP cells. 20 In fact, Finasteride has a Ki of 3.25 Â 10 À7 M for the type 1 isozyme and 1.2 Â 10 À8 M toward type 2 5-R. 20 In the present study, concentrations of 10 À7 -10 À8 M finasteride alone (without androgens) did not have an inhibitory effect on PSA production of LNCaP cells. PSA secretion induced by a fixed concentration of testosterone was decreased by finasteride in a dose-dependent manner although secretion induced by the same concentration of DHT did not have an inhibitory effect. These data also show that concentrations of 10 À7 -10 À8 M finasteride block type 2 5-R activity in LNCaP cells.
Previously, we indicated that serum levels of adrenal androgens in prostate cancer patients remained at about 60% following castration and flutamide, as opposed to testosterone levels that fell to about 2.7%. 21 Plasma levels of the sulfate form of DHEA in adult men are about 100-500 times higher than those of testosterone in the circulation in adult men. 22 It is believed that these large amounts of precursor adrenal androgens participate in prostate cancer recurrence after ADT. The transition of prostate cancer to androgen insensitivity can result from many different adaptive survival mechanisms. Point mutation in the steroid-binding domain of the AR gene, such as Thr877Ala, decreases binding specificity and Importance of androgen metabolism in prostate cancer K Suzuki et al allows activation of the AR-regulated gene by multiple steroid hormones including inactive precursor adrenal androgens. 23 AR amplification may also sensitize AR to activation by low levels of precursor adrenal androgens. 24 Moreover, in tumor cells overexpressing AR coactivators SRC-1 and TIF2, higher the AR activities were measured after treatment with precursor adrenal androgens. 25 Such data suggest that precursor adrenal androgens participate in the transition to androgen independency via mechanisms that relate to AR hypersensitivity. However, the intracellular actions of adrenal androgens and the identity of the androgens involved in AR binding are important in addition to these mechanisms potentially involved in the transition to androgen independence.
In the present study, the dose-dependent production of PSA induced by the antiandrogen hydroxy-flutamide in LNCaP cells was not inhibited by finasteride. Such data indicate that hydroxy-flutamide regulates PSA production via binding directly to the mutated AR with no influence of 5-R. The effect of testosterone on PSA regulation in LNCaP cells, however, was mediated via conversion to DHT, and this pathway might be more predominant than the direct binding of testosterone to a mutant receptor. Our data also show that the adrenal precursor androgens androstenedione, androstenediol and DHEA-induced PSA production in LNCaP cells via action of 5-R. These data indicate that the adrenal precursor androgens at least partly exert an effect not by directly interacting with AR but by undergoing enzymatic conversion to DHT, with consequent binding to the AR ( Figure 5 ).
We previously found that DHT levels in prostatic tissue after castration and flutamide therapy remained at approximately 25% of the amount measured before ADT in prostate cancer patients. 21 These data suggest that the source of DHT in the prostatic tissue after ADT involved intracrine production within the prostate, converting adrenal androgens into DHT. 21, 26 Whether the AR mutation characterized in the LNCaP cell line is present in a substantial number of patients with androgenindependent prostate cancer, and whether DHEA and androstenedione could induce PSA stimulatory effects by undergoing enzymatic conversion to more potent androgens in vivo found in the present in vitro study, remains to be clarified although the present data are highly suggestive of such an intracrine mechanism. If the results obtained with this human prostate cell line correspond to a biologic model closer to the hormonesensitive early stage of recurrent prostate cancer, we have shown the importance of the intracrine metabolism of adrenal androgens in many of prostate cancer patients at such stage. Such data emphasize that DHT made from adrenal precursors might play an important role in prostate cancer recurrence after ADT.
In fact, studies have established that therapy combining orchiectomy with antiandrogens to inhibit the action prostate cancer patients. [27] [28] [29] [30] Furthermore, an established 5-R inhibitor such as finasteride can reduce intraprostatic levels of DHT. 31 Finasteride prevents or delays the appearance of prostate cancer, 32 although it can increase the detection of high-grade cancer. Leibowits and Tucker have reported that triple androgen blockade, ADT followed by finasteride maintenance appears to be a promising alternative for the management of patients with clinically localized and locally advanced prostate cancer. 33 According to these findings and our studies, therapies that target the AR and prevent conversion from adrenal androgens to DHT within prostate cancer cells, such as treatment with a combination of 5-R inhibitors and anti-androgens, might offer the most effective ADT to prolong prostate cancer patient survival. Importance of androgen metabolism in prostate cancer K Suzuki et al
